Eye injection trial for rare vision disease halted early
NCT ID NCT03845049
Summary
This study tested whether aflibercept eye injections could reduce swelling in the retina caused by a rare eye disease called Macular Telangiectasia Type 1. It was a Phase 3 trial that planned to compare the drug against a placebo injection in 16 participants over 6 months. The trial was terminated early, and its results for improving or stabilizing vision are unknown.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU dijon Bourgogne
Dijon, 21000, France
Conditions
Explore the condition pages connected to this study.